Michael Narkewicz
Concepts (602)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 33 | 2025 | 1108 | 5.190 |
Why?
| | Liver Diseases | 24 | 2024 | 311 | 5.060 |
Why?
| | Liver Cirrhosis | 18 | 2023 | 316 | 3.110 |
Why?
| | Elasticity Imaging Techniques | 7 | 2024 | 60 | 2.870 |
Why?
| | Liver | 38 | 2023 | 1940 | 2.330 |
Why?
| | Hepatitis C, Chronic | 18 | 2024 | 164 | 2.180 |
Why?
| | Liver Failure, Acute | 13 | 2018 | 65 | 2.170 |
Why?
| | Hypertension, Portal | 9 | 2023 | 64 | 1.930 |
Why?
| | Liver Transplantation | 27 | 2023 | 871 | 1.660 |
Why?
| | Antiviral Agents | 17 | 2024 | 739 | 1.370 |
Why?
| | Gastroenterology | 7 | 2024 | 181 | 1.310 |
Why?
| | Interferon-alpha | 13 | 2013 | 198 | 1.200 |
Why?
| | Child | 89 | 2024 | 21819 | 1.030 |
Why?
| | Biliary Atresia | 9 | 2015 | 163 | 1.030 |
Why?
| | Child, Preschool | 66 | 2024 | 10997 | 0.890 |
Why?
| | Serine | 7 | 2002 | 141 | 0.810 |
Why?
| | Fontan Procedure | 3 | 2018 | 180 | 0.780 |
Why?
| | Pancreatitis | 3 | 2020 | 132 | 0.770 |
Why?
| | Ribavirin | 8 | 2020 | 91 | 0.760 |
Why?
| | Lymphoproliferative Disorders | 3 | 2013 | 55 | 0.760 |
Why?
| | Epstein-Barr Virus Infections | 4 | 2013 | 99 | 0.740 |
Why?
| | Esophageal Stenosis | 2 | 2018 | 54 | 0.720 |
Why?
| | Ursodeoxycholic Acid | 3 | 2016 | 21 | 0.690 |
Why?
| | Alanine Transaminase | 6 | 2016 | 157 | 0.680 |
Why?
| | gamma-Glutamyltransferase | 5 | 2016 | 43 | 0.680 |
Why?
| | Pancreatitis, Chronic | 2 | 2020 | 58 | 0.650 |
Why?
| | Liver Function Tests | 7 | 2016 | 114 | 0.630 |
Why?
| | Aspartate Aminotransferases | 3 | 2016 | 90 | 0.620 |
Why?
| | Humans | 129 | 2025 | 136803 | 0.620 |
Why?
| | Cholestasis | 7 | 2022 | 232 | 0.620 |
Why?
| | Bile Ducts | 3 | 2013 | 71 | 0.600 |
Why?
| | Adolescent | 60 | 2025 | 21385 | 0.580 |
Why?
| | Platelet Count | 3 | 2024 | 86 | 0.580 |
Why?
| | Infant | 46 | 2019 | 9395 | 0.570 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 6 | 2023 | 326 | 0.570 |
Why?
| | Postoperative Complications | 7 | 2018 | 2639 | 0.560 |
Why?
| | Esophageal and Gastric Varices | 5 | 2022 | 40 | 0.560 |
Why?
| | Feces | 3 | 2024 | 481 | 0.550 |
Why?
| | Hepacivirus | 8 | 2024 | 261 | 0.550 |
Why?
| | Hepatitis, Autoimmune | 1 | 2017 | 20 | 0.530 |
Why?
| | Disease Management | 2 | 2018 | 624 | 0.530 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 110 | 0.530 |
Why?
| | Female | 93 | 2025 | 72816 | 0.520 |
Why?
| | Benzodioxoles | 4 | 2025 | 115 | 0.510 |
Why?
| | Pyrrolidines | 4 | 2025 | 80 | 0.510 |
Why?
| | Benzimidazoles | 4 | 2024 | 170 | 0.500 |
Why?
| | Male | 80 | 2025 | 67330 | 0.490 |
Why?
| | Glycine | 6 | 2002 | 175 | 0.480 |
Why?
| | Aminophenols | 4 | 2025 | 156 | 0.480 |
Why?
| | Liver Failure | 3 | 2013 | 94 | 0.480 |
Why?
| | Pediatrics | 5 | 2020 | 1094 | 0.470 |
Why?
| | Physical Examination | 2 | 2018 | 240 | 0.450 |
Why?
| | Quinolones | 3 | 2025 | 137 | 0.440 |
Why?
| | Drug Combinations | 6 | 2025 | 343 | 0.430 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2016 | 228 | 0.430 |
Why?
| | Prospective Studies | 17 | 2025 | 7573 | 0.410 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2013 | 18 | 0.400 |
Why?
| | Gastrointestinal Hemorrhage | 6 | 2022 | 132 | 0.400 |
Why?
| | Indoles | 3 | 2025 | 410 | 0.400 |
Why?
| | Autoantibodies | 3 | 2017 | 1496 | 0.390 |
Why?
| | Acetamides | 1 | 2013 | 36 | 0.390 |
Why?
| | Infant, Newborn | 18 | 2018 | 6032 | 0.390 |
Why?
| | Colonoscopy | 1 | 2015 | 245 | 0.390 |
Why?
| | Hepatitis B, Chronic | 3 | 2010 | 23 | 0.390 |
Why?
| | Gastrointestinal Microbiome | 2 | 2024 | 698 | 0.390 |
Why?
| | Educational Measurement | 1 | 2015 | 280 | 0.380 |
Why?
| | Carbamates | 2 | 2024 | 49 | 0.380 |
Why?
| | Sheep | 8 | 2002 | 856 | 0.370 |
Why?
| | Mutation | 4 | 2023 | 3947 | 0.370 |
Why?
| | Heart Defects, Congenital | 2 | 2018 | 833 | 0.360 |
Why?
| | Chloride Channel Agonists | 5 | 2025 | 84 | 0.360 |
Why?
| | Carbon Dioxide | 2 | 2013 | 267 | 0.350 |
Why?
| | Cohort Studies | 12 | 2023 | 5704 | 0.340 |
Why?
| | Folic Acid | 2 | 2002 | 185 | 0.340 |
Why?
| | Blindness | 1 | 2010 | 38 | 0.330 |
Why?
| | Ultrasonography | 5 | 2020 | 752 | 0.330 |
Why?
| | Polyethylene Glycols | 9 | 2013 | 640 | 0.330 |
Why?
| | Prognosis | 15 | 2020 | 4013 | 0.320 |
Why?
| | Clinical Competence | 3 | 2020 | 1094 | 0.320 |
Why?
| | Retinal Diseases | 1 | 2010 | 91 | 0.320 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 621 | 0.320 |
Why?
| | Uridine Monophosphate | 2 | 2019 | 15 | 0.310 |
Why?
| | Uveitis | 1 | 2010 | 134 | 0.310 |
Why?
| | Optic Neuritis | 1 | 2009 | 41 | 0.310 |
Why?
| | Fluorenes | 2 | 2019 | 44 | 0.300 |
Why?
| | Esophagoscopy | 3 | 2018 | 209 | 0.290 |
Why?
| | Research | 2 | 2002 | 448 | 0.290 |
Why?
| | Sofosbuvir | 3 | 2024 | 62 | 0.290 |
Why?
| | Recombinant Proteins | 12 | 2013 | 1350 | 0.280 |
Why?
| | ROC Curve | 3 | 2019 | 545 | 0.280 |
Why?
| | Hepatitis C | 4 | 2012 | 267 | 0.280 |
Why?
| | Prevalence | 5 | 2017 | 2710 | 0.280 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2412 | 0.280 |
Why?
| | Glycine Hydroxymethyltransferase | 4 | 2001 | 16 | 0.270 |
Why?
| | Biomarkers | 11 | 2022 | 4145 | 0.270 |
Why?
| | Severity of Illness Index | 10 | 2020 | 2822 | 0.270 |
Why?
| | Pyrazoles | 3 | 2025 | 423 | 0.270 |
Why?
| | Sulfonamides | 2 | 2021 | 513 | 0.260 |
Why?
| | Pyridines | 3 | 2025 | 506 | 0.260 |
Why?
| | Canada | 4 | 2018 | 421 | 0.240 |
Why?
| | Immediate-Early Proteins | 1 | 2005 | 49 | 0.240 |
Why?
| | Cholestasis, Intrahepatic | 3 | 2003 | 39 | 0.240 |
Why?
| | Galactose | 2 | 2003 | 33 | 0.240 |
Why?
| | Biliary Tract Diseases | 2 | 2002 | 39 | 0.230 |
Why?
| | Alagille Syndrome | 2 | 2022 | 33 | 0.230 |
Why?
| | Quality of Health Care | 1 | 2009 | 634 | 0.220 |
Why?
| | Lung Diseases | 2 | 2018 | 768 | 0.220 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 20 | 0.220 |
Why?
| | Transfusion Reaction | 1 | 2004 | 46 | 0.220 |
Why?
| | Treatment Outcome | 20 | 2024 | 10748 | 0.220 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 382 | 0.210 |
Why?
| | Ascites | 2 | 2015 | 46 | 0.210 |
Why?
| | Retrospective Studies | 17 | 2018 | 15510 | 0.210 |
Why?
| | Mass Screening | 2 | 2023 | 1267 | 0.210 |
Why?
| | Young Adult | 11 | 2025 | 13129 | 0.200 |
Why?
| | Follow-Up Studies | 10 | 2022 | 5106 | 0.200 |
Why?
| | Case-Control Studies | 8 | 2020 | 3540 | 0.200 |
Why?
| | Disease Progression | 5 | 2020 | 2751 | 0.200 |
Why?
| | Platelet Activation | 1 | 2003 | 93 | 0.200 |
Why?
| | Bilirubin | 5 | 2015 | 97 | 0.190 |
Why?
| | Placenta | 4 | 2010 | 749 | 0.190 |
Why?
| | Paracentesis | 1 | 2001 | 14 | 0.180 |
Why?
| | Choledochal Cyst | 3 | 2013 | 19 | 0.180 |
Why?
| | Hepatocytes | 1 | 2002 | 220 | 0.180 |
Why?
| | Registries | 5 | 2018 | 2015 | 0.180 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 2 | 2006 | 211 | 0.180 |
Why?
| | United States | 8 | 2020 | 14691 | 0.180 |
Why?
| | Herpesvirus 4, Human | 3 | 2013 | 167 | 0.180 |
Why?
| | Portoenterostomy, Hepatic | 4 | 2015 | 46 | 0.180 |
Why?
| | Quinoxalines | 1 | 2021 | 66 | 0.170 |
Why?
| | Menstruation | 1 | 2020 | 43 | 0.170 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 480 | 0.170 |
Why?
| | Insulin | 5 | 2025 | 2406 | 0.170 |
Why?
| | Risk Factors | 10 | 2018 | 10332 | 0.170 |
Why?
| | Uracil | 1 | 2020 | 31 | 0.170 |
Why?
| | Consensus | 1 | 2023 | 678 | 0.170 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 18 | 0.170 |
Why?
| | Cyclopropanes | 1 | 2020 | 90 | 0.170 |
Why?
| | Lactams, Macrocyclic | 1 | 2020 | 49 | 0.160 |
Why?
| | Acute Disease | 3 | 2016 | 1007 | 0.160 |
Why?
| | Anilides | 1 | 2020 | 73 | 0.160 |
Why?
| | Bile Acids and Salts | 2 | 2016 | 200 | 0.160 |
Why?
| | Adult | 24 | 2025 | 37643 | 0.160 |
Why?
| | Ritonavir | 1 | 2020 | 74 | 0.160 |
Why?
| | Postoperative Care | 2 | 2019 | 261 | 0.160 |
Why?
| | Proline | 1 | 2020 | 79 | 0.160 |
Why?
| | Drug Therapy, Combination | 7 | 2020 | 1062 | 0.150 |
Why?
| | Hepatitis, Chronic | 2 | 1995 | 5 | 0.150 |
Why?
| | Hepatic Encephalopathy | 5 | 2013 | 21 | 0.150 |
Why?
| | Databases, Factual | 4 | 2015 | 1351 | 0.150 |
Why?
| | Biopsy | 8 | 2019 | 1124 | 0.150 |
Why?
| | Neonatal Screening | 3 | 2016 | 169 | 0.150 |
Why?
| | Phosphoenolpyruvate Carboxykinase (GTP) | 4 | 1993 | 32 | 0.150 |
Why?
| | Carrier Proteins | 3 | 2016 | 769 | 0.150 |
Why?
| | Common Bile Duct Diseases | 1 | 1998 | 3 | 0.150 |
Why?
| | Electrocoagulation | 1 | 2018 | 40 | 0.150 |
Why?
| | Dilatation | 1 | 2018 | 66 | 0.150 |
Why?
| | Longitudinal Studies | 4 | 2019 | 2829 | 0.140 |
Why?
| | Fluoroscopy | 1 | 2018 | 153 | 0.140 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 209 | 0.140 |
Why?
| | Exercise Test | 2 | 2018 | 625 | 0.140 |
Why?
| | Pyruvic Acid | 2 | 2017 | 53 | 0.140 |
Why?
| | Epidermolysis Bullosa | 1 | 2018 | 67 | 0.140 |
Why?
| | Age Factors | 4 | 2017 | 3286 | 0.140 |
Why?
| | Survival Rate | 8 | 2019 | 1964 | 0.140 |
Why?
| | Logistic Models | 3 | 2017 | 2067 | 0.130 |
Why?
| | Graft Rejection | 2 | 2013 | 620 | 0.130 |
Why?
| | Sustained Virologic Response | 3 | 2024 | 40 | 0.130 |
Why?
| | Trypsin Inhibitor, Kazal Pancreatic | 1 | 2016 | 6 | 0.130 |
Why?
| | Trypsin | 1 | 2016 | 77 | 0.130 |
Why?
| | Lactic Acid | 2 | 2017 | 305 | 0.130 |
Why?
| | Mitochondrial Diseases | 1 | 2017 | 91 | 0.120 |
Why?
| | Blood Glucose | 2 | 2025 | 2181 | 0.120 |
Why?
| | Autoimmune Diseases | 3 | 2013 | 460 | 0.120 |
Why?
| | Growth Disorders | 2 | 2015 | 86 | 0.120 |
Why?
| | Lung Transplantation | 1 | 2019 | 313 | 0.120 |
Why?
| | Preoperative Care | 2 | 2019 | 356 | 0.120 |
Why?
| | Zinc | 1 | 1999 | 297 | 0.120 |
Why?
| | Fetus | 3 | 2000 | 806 | 0.120 |
Why?
| | Recurrence | 3 | 2016 | 1055 | 0.120 |
Why?
| | Parenteral Nutrition, Total | 1 | 1995 | 26 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2016 | 307 | 0.120 |
Why?
| | Cells, Cultured | 8 | 2015 | 4192 | 0.120 |
Why?
| | Fatty Liver | 2 | 2012 | 243 | 0.120 |
Why?
| | Capsule Endoscopes | 1 | 2015 | 7 | 0.120 |
Why?
| | Kidney | 2 | 2001 | 1467 | 0.120 |
Why?
| | Hepatitis B | 1 | 1995 | 70 | 0.120 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2015 | 31 | 0.120 |
Why?
| | Incidence | 3 | 2018 | 2797 | 0.120 |
Why?
| | Glucokinase | 3 | 1991 | 15 | 0.110 |
Why?
| | Quality of Life | 4 | 2022 | 2878 | 0.110 |
Why?
| | Sensitivity and Specificity | 2 | 2018 | 1936 | 0.110 |
Why?
| | RNA, Messenger | 5 | 2005 | 2831 | 0.110 |
Why?
| | Permeability | 1 | 2015 | 161 | 0.110 |
Why?
| | Prothrombin Time | 4 | 2012 | 35 | 0.110 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 225 | 0.110 |
Why?
| | Animals, Newborn | 2 | 2001 | 844 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 888 | 0.110 |
Why?
| | Cysteine | 1 | 1995 | 204 | 0.110 |
Why?
| | Cross-Sectional Studies | 4 | 2018 | 5424 | 0.110 |
Why?
| | Curriculum | 1 | 2020 | 976 | 0.100 |
Why?
| | Insulin-Like Growth Factor II | 1 | 1993 | 22 | 0.100 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 78 | 0.100 |
Why?
| | Amino Acids | 2 | 1996 | 497 | 0.100 |
Why?
| | Hepatitis, Viral, Human | 2 | 2006 | 25 | 0.100 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 81 | 0.100 |
Why?
| | Lymphocyte Activation | 2 | 2015 | 1150 | 0.100 |
Why?
| | Risk Assessment | 4 | 2020 | 3434 | 0.100 |
Why?
| | Cognition | 2 | 2011 | 1146 | 0.100 |
Why?
| | Decision Making | 1 | 2019 | 898 | 0.090 |
Why?
| | Acetylcysteine | 1 | 2013 | 145 | 0.090 |
Why?
| | Chronic Disease | 6 | 2010 | 1786 | 0.090 |
Why?
| | Professional Competence | 1 | 2013 | 100 | 0.090 |
Why?
| | DNA, Viral | 4 | 2010 | 363 | 0.090 |
Why?
| | Glucose | 4 | 2002 | 1019 | 0.090 |
Why?
| | Lipid Metabolism | 1 | 1995 | 512 | 0.090 |
Why?
| | Algorithms | 1 | 2019 | 1690 | 0.090 |
Why?
| | Diffuse Cerebral Sclerosis of Schilder | 1 | 1991 | 4 | 0.090 |
Why?
| | Time Factors | 11 | 2019 | 6809 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2015 | 1095 | 0.090 |
Why?
| | United Kingdom | 2 | 2009 | 310 | 0.090 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1993 | 316 | 0.090 |
Why?
| | Triiodothyronine | 1 | 1990 | 43 | 0.090 |
Why?
| | Behavior | 1 | 2011 | 90 | 0.090 |
Why?
| | Pregnancy | 9 | 2010 | 6729 | 0.090 |
Why?
| | Embryonic and Fetal Development | 2 | 2001 | 97 | 0.090 |
Why?
| | Animals | 18 | 2002 | 36850 | 0.090 |
Why?
| | Lauric Acids | 1 | 2010 | 4 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2018 | 1046 | 0.080 |
Why?
| | Clinical Chemistry Tests | 1 | 2010 | 11 | 0.080 |
Why?
| | Malabsorption Syndromes | 1 | 2010 | 16 | 0.080 |
Why?
| | Vitamin A Deficiency | 2 | 2005 | 26 | 0.080 |
Why?
| | Fetal Blood | 2 | 2010 | 327 | 0.080 |
Why?
| | Internship and Residency | 1 | 2020 | 1133 | 0.080 |
Why?
| | Natriuretic Peptides | 1 | 2009 | 9 | 0.080 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2010 | 65 | 0.080 |
Why?
| | Up-Regulation | 1 | 2013 | 844 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3265 | 0.080 |
Why?
| | Suture Techniques | 1 | 2010 | 121 | 0.080 |
Why?
| | Enzymes | 1 | 2010 | 67 | 0.080 |
Why?
| | Digestive System Surgical Procedures | 1 | 2010 | 106 | 0.080 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2009 | 25 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1507 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2015 | 913 | 0.080 |
Why?
| | Optic Nerve | 1 | 2009 | 64 | 0.080 |
Why?
| | Genotype | 3 | 2024 | 1914 | 0.080 |
Why?
| | Roseolovirus Infections | 1 | 2009 | 8 | 0.080 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2009 | 14 | 0.080 |
Why?
| | Protozoan Infections | 1 | 1989 | 11 | 0.080 |
Why?
| | Amino Acid Oxidoreductases | 2 | 2001 | 19 | 0.080 |
Why?
| | Transferases | 2 | 2001 | 33 | 0.080 |
Why?
| | Agammaglobulinemia | 1 | 2009 | 34 | 0.080 |
Why?
| | Hospitalization | 2 | 2016 | 2184 | 0.080 |
Why?
| | Interferon-gamma | 2 | 2015 | 789 | 0.080 |
Why?
| | Multienzyme Complexes | 2 | 2001 | 67 | 0.070 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2011 | 26 | 0.070 |
Why?
| | Vitamin E | 6 | 2005 | 124 | 0.070 |
Why?
| | Body Composition | 1 | 2012 | 679 | 0.070 |
Why?
| | Dietary Fats | 1 | 2010 | 304 | 0.070 |
Why?
| | Gastroenteritis | 1 | 1989 | 68 | 0.070 |
Why?
| | Societies, Medical | 3 | 2013 | 817 | 0.070 |
Why?
| | Lung | 2 | 2012 | 4063 | 0.070 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1989 | 232 | 0.070 |
Why?
| | Ischemia | 1 | 2010 | 407 | 0.070 |
Why?
| | Abdomen, Acute | 1 | 2006 | 21 | 0.070 |
Why?
| | Fatty Acids | 1 | 2010 | 442 | 0.070 |
Why?
| | Bile Duct Diseases | 1 | 2006 | 14 | 0.070 |
Why?
| | Survival Analysis | 5 | 2013 | 1321 | 0.070 |
Why?
| | Vitamin A | 2 | 2005 | 58 | 0.070 |
Why?
| | Hemophilia A | 1 | 1989 | 139 | 0.060 |
Why?
| | Child Behavior | 1 | 2009 | 246 | 0.060 |
Why?
| | Interleukin-12 | 1 | 2006 | 121 | 0.060 |
Why?
| | Research Design | 1 | 2012 | 1127 | 0.060 |
Why?
| | Hypertension, Pulmonary | 2 | 2009 | 1905 | 0.060 |
Why?
| | Laparoscopy | 1 | 2010 | 464 | 0.060 |
Why?
| | Biliary Tract | 1 | 2005 | 17 | 0.060 |
Why?
| | Emotions | 1 | 2011 | 545 | 0.060 |
Why?
| | Connective Tissue Growth Factor | 1 | 2005 | 25 | 0.060 |
Why?
| | Copper | 2 | 1998 | 104 | 0.060 |
Why?
| | Influenza A virus | 1 | 2006 | 110 | 0.060 |
Why?
| | Autopsy | 1 | 2005 | 93 | 0.060 |
Why?
| | Glycogen Storage Disease Type IV | 1 | 2005 | 4 | 0.060 |
Why?
| | 1,4-alpha-Glucan Branching Enzyme | 1 | 2005 | 4 | 0.060 |
Why?
| | Bile | 1 | 2005 | 34 | 0.060 |
Why?
| | In Situ Hybridization | 1 | 2005 | 316 | 0.060 |
Why?
| | Culture Media | 3 | 1996 | 165 | 0.060 |
Why?
| | Predictive Value of Tests | 4 | 2013 | 2022 | 0.060 |
Why?
| | Carnitine | 1 | 2005 | 84 | 0.060 |
Why?
| | Endoscopy | 2 | 1998 | 318 | 0.060 |
Why?
| | Acetyl-CoA Carboxylase | 3 | 1995 | 33 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2010 | 825 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1993 | 0.060 |
Why?
| | Drug Resistance, Viral | 2 | 2018 | 116 | 0.060 |
Why?
| | Glucagon | 3 | 2002 | 109 | 0.050 |
Why?
| | Benzopyrans | 1 | 2024 | 26 | 0.050 |
Why?
| | Quinolines | 1 | 2025 | 177 | 0.050 |
Why?
| | Mothers | 1 | 2010 | 752 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2025 | 364 | 0.050 |
Why?
| | Disease Transmission, Infectious | 1 | 2004 | 62 | 0.050 |
Why?
| | Lupus Erythematosus, Cutaneous | 1 | 2003 | 8 | 0.050 |
Why?
| | Respiratory Function Tests | 2 | 2018 | 595 | 0.050 |
Why?
| | Kinetics | 3 | 2000 | 1664 | 0.050 |
Why?
| | Platelet Factor 4 | 1 | 2003 | 35 | 0.050 |
Why?
| | Blood Donors | 1 | 2004 | 103 | 0.050 |
Why?
| | Endoglin | 1 | 2022 | 19 | 0.050 |
Why?
| | Blood Coagulation Tests | 1 | 2003 | 67 | 0.050 |
Why?
| | Pyrroles | 1 | 2024 | 213 | 0.050 |
Why?
| | Carbon Radioisotopes | 2 | 2000 | 34 | 0.050 |
Why?
| | Anastomosis, Surgical | 2 | 2011 | 152 | 0.050 |
Why?
| | Pancreatic Elastase | 1 | 2022 | 58 | 0.050 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2022 | 26 | 0.050 |
Why?
| | Niemann-Pick Diseases | 1 | 2002 | 2 | 0.050 |
Why?
| | Bromodeoxyuridine | 1 | 2002 | 80 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2015 | 1316 | 0.050 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2004 | 182 | 0.050 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2003 | 165 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1798 | 0.050 |
Why?
| | Pilot Projects | 4 | 2006 | 1693 | 0.050 |
Why?
| | Dysbiosis | 1 | 2024 | 181 | 0.050 |
Why?
| | International Normalized Ratio | 2 | 2012 | 47 | 0.050 |
Why?
| | Enzyme Induction | 2 | 1993 | 90 | 0.050 |
Why?
| | Umbilical Veins | 1 | 2002 | 61 | 0.050 |
Why?
| | Somatostatin | 1 | 2002 | 61 | 0.050 |
Why?
| | Plasma Volume | 1 | 2001 | 19 | 0.050 |
Why?
| | Punctures | 1 | 2001 | 39 | 0.050 |
Why?
| | Cholangitis | 1 | 2001 | 20 | 0.050 |
Why?
| | Weaning | 4 | 1995 | 47 | 0.050 |
Why?
| | Interleukin-8 | 1 | 2022 | 268 | 0.050 |
Why?
| | Oxidoreductases Acting on CH-NH Group Donors | 1 | 2001 | 2 | 0.050 |
Why?
| | 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2001 | 18 | 0.050 |
Why?
| | Constipation | 1 | 2022 | 94 | 0.050 |
Why?
| | Patient Selection | 2 | 2019 | 691 | 0.050 |
Why?
| | Genotyping Techniques | 1 | 2021 | 75 | 0.040 |
Why?
| | Health Status | 2 | 2022 | 788 | 0.040 |
Why?
| | Tetrahydrofolates | 1 | 2001 | 18 | 0.040 |
Why?
| | Caregivers | 1 | 2009 | 870 | 0.040 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2002 | 107 | 0.040 |
Why?
| | Chlorides | 1 | 2022 | 136 | 0.040 |
Why?
| | Needles | 1 | 2001 | 59 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1733 | 0.040 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2001 | 36 | 0.040 |
Why?
| | Cardiomyopathies | 1 | 2005 | 348 | 0.040 |
Why?
| | Leucovorin | 1 | 2001 | 82 | 0.040 |
Why?
| | RNA, Viral | 2 | 2010 | 654 | 0.040 |
Why?
| | North America | 1 | 2002 | 312 | 0.040 |
Why?
| | Catheterization | 1 | 2001 | 179 | 0.040 |
Why?
| | Drainage | 1 | 2001 | 171 | 0.040 |
Why?
| | 2-Naphthylamine | 1 | 2020 | 7 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2003 | 655 | 0.040 |
Why?
| | Stress, Psychological | 1 | 2009 | 1097 | 0.040 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2020 | 13 | 0.040 |
Why?
| | Intestinal Absorption | 2 | 2010 | 102 | 0.040 |
Why?
| | Tablets | 1 | 2020 | 40 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 116 | 0.040 |
Why?
| | Influenza, Human | 1 | 2006 | 618 | 0.040 |
Why?
| | Gestational Age | 2 | 2002 | 902 | 0.040 |
Why?
| | Nutritional Status | 2 | 2015 | 344 | 0.040 |
Why?
| | Accreditation | 1 | 2020 | 82 | 0.040 |
Why?
| | Phosphoglycerate Dehydrogenase | 1 | 1999 | 6 | 0.040 |
Why?
| | Hepatitis B virus | 2 | 2010 | 40 | 0.040 |
Why?
| | Carbohydrate Dehydrogenases | 1 | 1999 | 11 | 0.040 |
Why?
| | Valine | 1 | 2020 | 82 | 0.040 |
Why?
| | Animals, Suckling | 3 | 1995 | 10 | 0.040 |
Why?
| | Binding, Competitive | 1 | 2000 | 202 | 0.040 |
Why?
| | Transaminases | 1 | 1999 | 24 | 0.040 |
Why?
| | Blood Platelets | 1 | 2003 | 407 | 0.040 |
Why?
| | Competency-Based Education | 1 | 2020 | 73 | 0.040 |
Why?
| | Rabbits | 1 | 2001 | 792 | 0.040 |
Why?
| | Syndrome | 2 | 2009 | 357 | 0.040 |
Why?
| | Leucine | 1 | 2000 | 111 | 0.040 |
Why?
| | Safety | 1 | 2001 | 338 | 0.040 |
Why?
| | Pruritus | 1 | 1999 | 63 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2023 | 951 | 0.040 |
Why?
| | Referral and Consultation | 2 | 2019 | 780 | 0.040 |
Why?
| | Rats | 6 | 1995 | 5639 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2005 | 1094 | 0.040 |
Why?
| | Rifampin | 1 | 1999 | 84 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 1991 | 283 | 0.040 |
Why?
| | Hypersplenism | 1 | 1998 | 8 | 0.040 |
Why?
| | Heart | 1 | 2003 | 653 | 0.040 |
Why?
| | Isoenzymes | 1 | 1999 | 304 | 0.040 |
Why?
| | Lipids | 4 | 2002 | 665 | 0.040 |
Why?
| | Biological Transport | 1 | 2000 | 416 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2001 | 328 | 0.040 |
Why?
| | Duodenoscopy | 1 | 1998 | 7 | 0.040 |
Why?
| | Medicine | 1 | 2020 | 121 | 0.040 |
Why?
| | Pemoline | 1 | 1998 | 4 | 0.040 |
Why?
| | Gluconeogenesis | 2 | 2002 | 79 | 0.040 |
Why?
| | Sphincterotomy, Endoscopic | 1 | 1998 | 28 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1772 | 0.040 |
Why?
| | Rats, Inbred Strains | 4 | 1990 | 362 | 0.040 |
Why?
| | Genes, Viral | 1 | 1998 | 88 | 0.040 |
Why?
| | Gallstones | 1 | 1998 | 31 | 0.040 |
Why?
| | Reoviridae | 1 | 1998 | 37 | 0.040 |
Why?
| | Serum Albumin | 1 | 1999 | 150 | 0.040 |
Why?
| | Technetium Tc 99m Disofenin | 1 | 1998 | 3 | 0.040 |
Why?
| | Age Distribution | 1 | 2019 | 390 | 0.040 |
Why?
| | Postoperative Period | 1 | 1999 | 343 | 0.040 |
Why?
| | Reoviridae Infections | 1 | 1998 | 54 | 0.040 |
Why?
| | Medical History Taking | 1 | 2018 | 117 | 0.040 |
Why?
| | Hemodynamics | 1 | 2003 | 1110 | 0.040 |
Why?
| | Half-Life | 1 | 1998 | 164 | 0.040 |
Why?
| | Pancreatic Diseases | 1 | 1998 | 72 | 0.030 |
Why?
| | Manganese | 1 | 1998 | 62 | 0.030 |
Why?
| | Pancreas Transplantation | 1 | 2017 | 75 | 0.030 |
Why?
| | Caffeine | 1 | 1998 | 68 | 0.030 |
Why?
| | Reference Values | 1 | 1999 | 816 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2019 | 204 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 65 | 0.030 |
Why?
| | Creatinine | 1 | 1999 | 499 | 0.030 |
Why?
| | Ammonia | 2 | 2008 | 62 | 0.030 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1998 | 136 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 303 | 0.030 |
Why?
| | Esophagus | 1 | 2018 | 255 | 0.030 |
Why?
| | Injections, Subcutaneous | 2 | 2006 | 154 | 0.030 |
Why?
| | Central Nervous System Stimulants | 1 | 1998 | 161 | 0.030 |
Why?
| | Embolization, Therapeutic | 1 | 1998 | 229 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2010 | 785 | 0.030 |
Why?
| | Hypoalbuminemia | 1 | 2015 | 30 | 0.030 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2015 | 35 | 0.030 |
Why?
| | CHO Cells | 1 | 1996 | 161 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 481 | 0.030 |
Why?
| | Cricetinae | 1 | 1996 | 289 | 0.030 |
Why?
| | Food, Fortified | 1 | 1995 | 41 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 1998 | 562 | 0.030 |
Why?
| | Radiography | 1 | 1998 | 822 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2015 | 98 | 0.030 |
Why?
| | Body Mass Index | 2 | 2015 | 2375 | 0.030 |
Why?
| | Cytosol | 1 | 1996 | 226 | 0.030 |
Why?
| | Solubility | 2 | 2013 | 245 | 0.030 |
Why?
| | Glycerol | 1 | 1995 | 94 | 0.030 |
Why?
| | Brain | 2 | 2001 | 2664 | 0.030 |
Why?
| | Hepatolenticular Degeneration | 1 | 1994 | 15 | 0.030 |
Why?
| | Transcription, Genetic | 2 | 1999 | 1455 | 0.030 |
Why?
| | Remission Induction | 1 | 1995 | 288 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 1995 | 431 | 0.030 |
Why?
| | Ileum | 1 | 1995 | 119 | 0.030 |
Why?
| | Echocardiography | 2 | 2009 | 643 | 0.030 |
Why?
| | Mitochondria, Liver | 1 | 1994 | 73 | 0.030 |
Why?
| | Random Allocation | 1 | 1995 | 353 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 2015 | 216 | 0.030 |
Why?
| | Inflammation | 1 | 2005 | 2835 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1262 | 0.030 |
Why?
| | Oxidants | 1 | 1994 | 111 | 0.030 |
Why?
| | Lipid Peroxidation | 2 | 1994 | 153 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 455 | 0.030 |
Why?
| | Choline | 1 | 1995 | 127 | 0.030 |
Why?
| | Immunosuppressive Agents | 3 | 2007 | 889 | 0.030 |
Why?
| | Vitamin E Deficiency | 2 | 1991 | 43 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2013 | 61 | 0.030 |
Why?
| | Prednisone | 1 | 1994 | 239 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2015 | 250 | 0.030 |
Why?
| | Thymidine | 1 | 1993 | 60 | 0.030 |
Why?
| | Cyclosporine | 1 | 1994 | 268 | 0.030 |
Why?
| | Lactates | 1 | 1993 | 85 | 0.030 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2013 | 10 | 0.030 |
Why?
| | Fatty Acid Synthases | 2 | 1990 | 24 | 0.030 |
Why?
| | Colon | 1 | 1995 | 282 | 0.020 |
Why?
| | Biomarkers, Pharmacological | 1 | 2012 | 28 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2013 | 88 | 0.020 |
Why?
| | Pseudomonas aeruginosa | 1 | 2015 | 352 | 0.020 |
Why?
| | Polymerase Chain Reaction | 3 | 2002 | 1059 | 0.020 |
Why?
| | Eating | 2 | 2012 | 379 | 0.020 |
Why?
| | Cell Separation | 1 | 1993 | 317 | 0.020 |
Why?
| | Aging | 2 | 2001 | 1864 | 0.020 |
Why?
| | Signal Transduction | 1 | 2005 | 5077 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 412 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1180 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2013 | 319 | 0.020 |
Why?
| | Vitamins | 2 | 1991 | 185 | 0.020 |
Why?
| | Cyclosporins | 1 | 1991 | 76 | 0.020 |
Why?
| | Hemochromatosis | 1 | 2011 | 10 | 0.020 |
Why?
| | Hyperbilirubinemia | 1 | 2011 | 13 | 0.020 |
Why?
| | Cell Division | 1 | 1993 | 796 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 199 | 0.020 |
Why?
| | Choledochostomy | 1 | 2011 | 11 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1301 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3556 | 0.020 |
Why?
| | Vital Capacity | 1 | 2012 | 311 | 0.020 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2011 | 28 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1572 | 0.020 |
Why?
| | Stimulation, Chemical | 1 | 1990 | 59 | 0.020 |
Why?
| | Status Epilepticus | 1 | 1991 | 50 | 0.020 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2010 | 24 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2064 | 0.020 |
Why?
| | Prader-Willi Syndrome | 1 | 2010 | 27 | 0.020 |
Why?
| | Decidua | 1 | 2010 | 24 | 0.020 |
Why?
| | Risk | 2 | 2005 | 908 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2012 | 531 | 0.020 |
Why?
| | Rectal Prolapse | 1 | 2010 | 23 | 0.020 |
Why?
| | Herpes Simplex | 1 | 2011 | 95 | 0.020 |
Why?
| | Lamivudine | 1 | 2010 | 63 | 0.020 |
Why?
| | Enzyme Therapy | 1 | 2010 | 4 | 0.020 |
Why?
| | Organophosphonates | 1 | 2010 | 93 | 0.020 |
Why?
| | Ligases | 1 | 1990 | 32 | 0.020 |
Why?
| | Natural Killer T-Cells | 1 | 2010 | 67 | 0.020 |
Why?
| | Neutropenia | 1 | 2010 | 146 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5744 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 1995 | 2486 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 2013 | 443 | 0.020 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 45 | 0.020 |
Why?
| | Legal Guardians | 1 | 2009 | 9 | 0.020 |
Why?
| | Herpesvirus 7, Human | 1 | 2009 | 6 | 0.020 |
Why?
| | Mitochondria | 1 | 1996 | 946 | 0.020 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2010 | 179 | 0.020 |
Why?
| | Hormones | 1 | 1990 | 142 | 0.020 |
Why?
| | Rectum | 1 | 2010 | 185 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2009 | 56 | 0.020 |
Why?
| | Opportunistic Infections | 1 | 1989 | 45 | 0.020 |
Why?
| | Vitamin D Deficiency | 1 | 1991 | 186 | 0.020 |
Why?
| | Adenine | 1 | 2010 | 270 | 0.020 |
Why?
| | Living Donors | 1 | 2011 | 295 | 0.020 |
Why?
| | Hypoglycemia | 1 | 1993 | 442 | 0.020 |
Why?
| | Gene Expression | 1 | 1993 | 1500 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2009 | 132 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 1982 | 0.020 |
Why?
| | Body Weight | 1 | 2012 | 985 | 0.020 |
Why?
| | Pancreas | 1 | 2010 | 329 | 0.020 |
Why?
| | Middle Aged | 5 | 2019 | 33239 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2010 | 484 | 0.020 |
Why?
| | Rupture, Spontaneous | 1 | 2006 | 17 | 0.020 |
Why?
| | Probability | 1 | 2007 | 304 | 0.020 |
Why?
| | Fibrosis | 1 | 2009 | 552 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1044 | 0.020 |
Why?
| | Treatment Failure | 1 | 2007 | 354 | 0.020 |
Why?
| | Interferon-beta | 1 | 2006 | 92 | 0.020 |
Why?
| | DNA | 1 | 1993 | 1458 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1990 | 2052 | 0.020 |
Why?
| | Glucocorticoids | 1 | 1990 | 593 | 0.020 |
Why?
| | Retinol-Binding Proteins | 1 | 2005 | 18 | 0.020 |
Why?
| | Skin Physiological Phenomena | 1 | 1985 | 25 | 0.020 |
Why?
| | Diterpenes | 1 | 2005 | 31 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2010 | 559 | 0.020 |
Why?
| | Cause of Death | 1 | 2007 | 430 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2006 | 570 | 0.010 |
Why?
| | Amylopectin | 1 | 2005 | 5 | 0.010 |
Why?
| | Esterification | 1 | 2005 | 9 | 0.010 |
Why?
| | Adipose Tissue | 1 | 1990 | 630 | 0.010 |
Why?
| | Electrodes | 1 | 1985 | 111 | 0.010 |
Why?
| | Reoperation | 1 | 2007 | 573 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2005 | 171 | 0.010 |
Why?
| | Dry Eye Syndromes | 1 | 2005 | 54 | 0.010 |
Why?
| | Viral Load | 1 | 2006 | 464 | 0.010 |
Why?
| | Oxygen Consumption | 2 | 2002 | 695 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2006 | 558 | 0.010 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2003 | 19 | 0.010 |
Why?
| | Needs Assessment | 1 | 2006 | 372 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1985 | 267 | 0.010 |
Why?
| | Antibodies, Antinuclear | 1 | 2003 | 71 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2003 | 132 | 0.010 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2003 | 200 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 813 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 1985 | 258 | 0.010 |
Why?
| | Splenomegaly | 1 | 2002 | 15 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1112 | 0.010 |
Why?
| | Ornithine | 1 | 2002 | 26 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2002 | 432 | 0.010 |
Why?
| | Medical Records | 1 | 2002 | 174 | 0.010 |
Why?
| | Cardiac Catheterization | 1 | 2005 | 527 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2005 | 382 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 629 | 0.010 |
Why?
| | Glutamine | 1 | 2002 | 103 | 0.010 |
Why?
| | Influenza Vaccines | 1 | 2006 | 537 | 0.010 |
Why?
| | Alanine | 1 | 2002 | 152 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 851 | 0.010 |
Why?
| | Vaccination | 1 | 2009 | 1377 | 0.010 |
Why?
| | Arginine | 1 | 2002 | 271 | 0.010 |
Why?
| | Parents | 1 | 2009 | 1340 | 0.010 |
Why?
| | DNA Probes | 2 | 1990 | 60 | 0.010 |
Why?
| | Fibroblasts | 1 | 2005 | 993 | 0.010 |
Why?
| | gamma-Globulins | 1 | 1998 | 18 | 0.010 |
Why?
| | Jaundice | 1 | 1998 | 14 | 0.010 |
Why?
| | Esophagoscopes | 1 | 1996 | 5 | 0.010 |
Why?
| | Endoscopes | 1 | 1996 | 17 | 0.010 |
Why?
| | Ligation | 1 | 1996 | 87 | 0.010 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1995 | 29 | 0.010 |
Why?
| | Ulcer | 1 | 1995 | 32 | 0.010 |
Why?
| | Azathioprine | 1 | 1994 | 54 | 0.010 |
Why?
| | Necrosis | 1 | 1995 | 245 | 0.010 |
Why?
| | Microsomes, Liver | 1 | 1994 | 86 | 0.010 |
Why?
| | Diarrhea | 1 | 1995 | 183 | 0.010 |
Why?
| | Fever | 1 | 1995 | 306 | 0.010 |
Why?
| | Drug Resistance | 1 | 1994 | 169 | 0.010 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 1998 | 413 | 0.010 |
Why?
| | Dogs | 1 | 1994 | 411 | 0.010 |
Why?
| | Linear Models | 1 | 1995 | 846 | 0.010 |
Why?
| | Length of Stay | 1 | 1998 | 1205 | 0.010 |
Why?
| | Acetaminophen | 1 | 1995 | 266 | 0.010 |
Why?
| | Regression Analysis | 1 | 1994 | 1022 | 0.010 |
Why?
| | Pancreatin | 1 | 1991 | 6 | 0.010 |
Why?
| | Taurocholic Acid | 1 | 1990 | 33 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1990 | 77 | 0.010 |
Why?
| | Hydroxycholecalciferols | 1 | 1989 | 3 | 0.010 |
Why?
| | Infant Nutrition Disorders | 1 | 1989 | 11 | 0.010 |
Why?
| | Vitamin K | 1 | 1989 | 45 | 0.000 |
Why?
| | Cell Survival | 1 | 1990 | 1116 | 0.000 |
Why?
| | Energy Intake | 1 | 1990 | 484 | 0.000 |
Why?
| | Iridium | 1 | 1985 | 7 | 0.000 |
Why?
| | Partial Pressure | 1 | 1985 | 30 | 0.000 |
Why?
| | Skin Temperature | 1 | 1985 | 30 | 0.000 |
Why?
| | Colorado | 1 | 1995 | 4515 | 0.000 |
Why?
| | Aged | 2 | 1994 | 23808 | 0.000 |
Why?
|
|
Narkewicz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|